Evaluation of the relationship between AGEs and treatment responsiveness of anti-VEGF in DME patients’

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON21659

Enrollment

Registered

2020-03-05

Start date

2020-03-05

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic retinopathy (DR)

Interventions

none

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with DME who started inravitreal anti-VEGF therapy less than 1 yr ago · Age: >18 years.

Exclusion criteria

Exclusion criteria: Dark coloured skin (Fitzpatrick type V or VI). · Skin abnormalities on both arms that will impair the reliability of the autofluorescence measurement. · Local or general active infection or inflammatory disease. · Known renal disease, current dialysis treatment, or a history of renal transplantation. · Patients with high myopia (>6 diopters), glaucoma, combined retinal disease, media opacities interfering with OCT imaging, vitreomacular traction on SD-OCT and those whose SD-OCT images were of poor quality, intraocular surgery within 12 weeks prior to the first injection

Design outcomes

Primary

Measure	Time frame
treatment success	—

Secondary

Measure	Time frame
1 year BCVA and macular thickness	—

Contacts

Public ContactL.I. Los

University Medical Center Groningen

l.i.los@umcg.nl050-3612510

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)